David Davidovic | Founder, pathForward, Former VP and Global Head, Commercial Services
Roche Genentech

David Davidovic, Founder, pathForward, Former VP and Global Head, Commercial Services, Roche Genentech

David Davidovic has been involved in the commercialization of products and in building best-in-class commercial capabilities in the pharmaceutical and biotechnology industries for over 37 years.  Most recently, David was Vice President and Global Head of Commercial Services for Roche and Genentech.  Currently, he heads pathForward, providing strategic and advisory pro-bono support to non-profit organizations as well as start-ups focused on healthcare.  David also serves on a number of company advisory boards and is a member of the Board of Directors of Clinica Verde, a global healthcare organization designing and operating sustainably designed community health hubs in Latin America.

David joined Genentech in 2005 as head of US Commercial Strategy; in 2007 he became head of the US Commercial Business Practices function; and in 2011 was appointed VP and Global Head of Commercial Services for Roche Pharma Medicines, which includes Genentech in the US.  Prior to joining Genentech, he spent over 23 years with Merck & Co. where he served in multiple marketing, sales, business development, medical education, and commercial operations leadership roles, including marketing, sales, business unit and franchise head positions, in Canada, the US, the Middle East and Africa and globally.  David was born and grew up in Quito, Ecuador; holds Bachelor of Science and a Masters in Business Administration degrees from McGill University in Montreal, Canada; and is based in San Francisco, CA.

Appearances:



Pharma Pricing & Market Access USA Day 1 @ 12:50

ROUND TABLES

1) US payer introduction to the structures and processes

  • Jennifer L. Bragg, Partner, FDA regulatory and litigation attorney
  • Asif Velani, Head of Market Access, Puma Biotechnology
2) Statistical methodologies- learning new meta analysis techniques
  • Andy Gunn, Global Head Evidence Generation, UCB BioPharmaceuticals Inc
  • Simon Semus, Observational Data Analyst, GSK
3) Policy framework- Patient data and evidence management
  • Amy Niles, Vice President, External Affairs, Patient Access Network Foundation
  • Leena Patel, President and CEO, PAN Foundation
4) Economic Evaluation of Vaccines- Providing value through the prevention of disease
  • David Davidovic, Former Vice President & Global Head, Commercial Services, Roche & Genentech
5) Value Frameworks - What is the future?
  • Christine Verini, Chief Business Development Officer, CancerCare
  • John Stoeckle, Physician, Thomas Jefferson University Hospitals, Inc
  • Susan Gabriel, Director, Global Health Economics and Outcomes Research, Teva Pharmaceuticals
6) Biosimilars - Market Access
  • Jennifer Voelker, HEOR fellow, Janssen
  • Sonia Lee, HEOR fellow, Ethicon
  • Ravi Iyer, Director Global Health Economics and Reimbursement, Teva
  • Ying Wu, Director HEOR, Teva
  • Ravi Iyer, Director Global Health Economics and Reimbursement, Teva
7) BioBetter Pricing Models- Discovering how biobetters are becoming mainstream
  • Boxiong Tang, Sr. Director, GHEOR, Teva
  • Riad Dirani, Vice President Global Health Economics & Outcomes Research & EBM Global Medical Affairs, Teva Pharmaceuticals
8) Dynamic Drug Pricing Frameworks- Converging supply and demand Uber style
  • Ben Locwin, Ex-Executive Director, Roche
9) EHR records- How to bennefit 
  • Yong Chen, Director of Real World Data & Analytics, GSK
10) Post Release Commercialization - When and how
  • Shailesh Chavan, Vice President, Clinical Research, Drug Safety & Medical Affairs, Biotest Pharmaceuticals

 

Economic Evaluation of Vaccines- Providing value through the prevention of disease

Pharma Pricing & Market Access USA Day 1 @ 16:10

Value and Impact of early collaboration between commercial and development

  • The importance and benefits of early and ongoing communications and collaboration
  • How can such collaboration be appropriate in the current regulatory environment?
  • How this collaboration is essential for patient centricity

back to speakers